Details
| Translated title of the contribution | Split-Combine Click-SELEX deckt Liganden auf, die den Transplantatabstoßungs-Biomarker CXCL9 erkennen |
|---|---|
| Original language | English |
| Pages (from-to) | 129-137 |
| Number of pages | 9 |
| Journal | ACS chemical biology |
| Volume | 17 |
| Issue number | 1 |
| Early online date | 12 Jan 2022 |
| Publication status | Published - 21 Jan 2022 |
Abstract
Renal rejection is a major incidence in patients after kidney transplantation and associated with allograft scarring and function loss, especially in antibody-mediated rejection. Regular clinical monitoring of kidney-transplanted patients is thus necessary, but measuring donor-specific antibodies is not always predictive, and graft biopsies are time-consuming and costly and may come up with a histological result unsuspicious for rejection. Therefore, a noninvasive diagnostic approach to estimate an increased probability of kidney graft rejection by measuring specific biomarkers is highly desired. The chemokine CXCL9 is described as an early indicator of rejection. In this work, we identified clickmers and an aptamer by split–combine click-SELEX (systematic evolution of ligands by exponential enrichment) that bind CXLC9 with high affinity. The aptamers recognize native CXCL9 and maintain binding properties under urine conditions. These features render the molecules as potential binding and detector probes for developing point-of-care devices, e.g., lateral flow assays, enabling the noninvasive monitoring of CXCL9 in renal allograft patients.
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Biochemistry
- Biochemistry, Genetics and Molecular Biology(all)
- Molecular Medicine
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: ACS chemical biology, Vol. 17, No. 1, 21.01.2022, p. 129-137.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - Split–Combine Click-SELEX Reveals Ligands Recognizing the Transplant Rejection Biomarker CXCL9
AU - Siegl, Julia
AU - Nikolin, Christoph
AU - Phung, Ngoc Linh
AU - Thoms, Stefanie
AU - Blume, Cornelia
AU - Mayer, Günter
N1 - Funding Information: This work was made possible by fund from the Federal Ministry of Economic Affairs and Energy to G.M. and C.B. (ZF 4613701CR8) and the German Research Foundation (DFG, MA3442/7-1) and the European Regional Development Fund (85006385) to C.B. We thank I. Förster for sharing aliquots of the various chemokines used for specificity testing.
PY - 2022/1/21
Y1 - 2022/1/21
N2 - Renal rejection is a major incidence in patients after kidney transplantation and associated with allograft scarring and function loss, especially in antibody-mediated rejection. Regular clinical monitoring of kidney-transplanted patients is thus necessary, but measuring donor-specific antibodies is not always predictive, and graft biopsies are time-consuming and costly and may come up with a histological result unsuspicious for rejection. Therefore, a noninvasive diagnostic approach to estimate an increased probability of kidney graft rejection by measuring specific biomarkers is highly desired. The chemokine CXCL9 is described as an early indicator of rejection. In this work, we identified clickmers and an aptamer by split–combine click-SELEX (systematic evolution of ligands by exponential enrichment) that bind CXLC9 with high affinity. The aptamers recognize native CXCL9 and maintain binding properties under urine conditions. These features render the molecules as potential binding and detector probes for developing point-of-care devices, e.g., lateral flow assays, enabling the noninvasive monitoring of CXCL9 in renal allograft patients.
AB - Renal rejection is a major incidence in patients after kidney transplantation and associated with allograft scarring and function loss, especially in antibody-mediated rejection. Regular clinical monitoring of kidney-transplanted patients is thus necessary, but measuring donor-specific antibodies is not always predictive, and graft biopsies are time-consuming and costly and may come up with a histological result unsuspicious for rejection. Therefore, a noninvasive diagnostic approach to estimate an increased probability of kidney graft rejection by measuring specific biomarkers is highly desired. The chemokine CXCL9 is described as an early indicator of rejection. In this work, we identified clickmers and an aptamer by split–combine click-SELEX (systematic evolution of ligands by exponential enrichment) that bind CXLC9 with high affinity. The aptamers recognize native CXCL9 and maintain binding properties under urine conditions. These features render the molecules as potential binding and detector probes for developing point-of-care devices, e.g., lateral flow assays, enabling the noninvasive monitoring of CXCL9 in renal allograft patients.
UR - http://www.scopus.com/inward/record.url?scp=85123368672&partnerID=8YFLogxK
U2 - 10.1021/acschembio.1c00789
DO - 10.1021/acschembio.1c00789
M3 - Article
C2 - 35018777
AN - SCOPUS:85123368672
VL - 17
SP - 129
EP - 137
JO - ACS chemical biology
JF - ACS chemical biology
SN - 1554-8929
IS - 1
ER -